The solution to the substantial risks associated with biotech stocks (especially small biotech firms)? Biotech ETFs! Today’s article highlights six biotech ETFs to consider buying, noting that “Some provide well-rounded access to the space, while others acutely focus on certain aspects of the space, such as cancer treatments or drugs to battle infectious diseases.” For these six biotech ETFs, CLICK HERE.
Today’s article highlights two “compelling small-cap stocks that combine a low cost of entry with the Street’s backing.” More specifically, these two stocks – a biotech firm and a pharmaceutical company – are currently trading for less than $8 a share, have earned “Strong Buy” consensus analyst ratings, and boast significant upside potential. For more, CLICK HERE.
Shares of the small-cap biotech stock highlighted in today’s article have settled back down after surging more than 70% earlier this month in reaction to interim results for the company’s only drug candidate to reach the clinical trial phase. Does that make now a good time to buy? For more on this “flaming hot” biotech firm that could “become a maverick in developing a therapeutic candidate for [a] significant medical need”, CLICK HERE.